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Material and methods. Patient of 59 years with no history of interest, which is detected in routine screening PSA elevation (8.3ng).
Biopsy: Gleason 3+4 adenocarcinoma (ADC) in 2/3 cylinders right lobe; left lobe (0/3). Prostate volume 25 cm3. Maximum ﬂowme-
try: 22.2ml/s. IPSS: 5. QLQ PR 25: 10 Urinary Incontinence 1, Intestinal 4, Sexual Activity 5, Functionality 8. Negative extension
study. ADC is diagnosed as intermediate risk prostate D’Amico groups say (cT1c). The patient refused surgery for what is referred
to our department to evaluate alternative healing less morbidity. Radiotherapy toyed three options: exclusive Brachytherapy
vs Brachytherapy+CRT vs CRT+short-term androgen deprivation. We opted for exclusive Brachytherapy being shorter treat-
ment which provides reduced toxicity. It makes permanent implant prostate Brachytherapy with I-125 seeds for a dose of PTV
(prostate +margin 5mm) of 145Gy.
Results. At the ﬁrst month post-Brachytherapy PSA levels reached 9.64ng/ml. At 6 months, the PSA down to 3.37 and the score
on the QLQ PR 25 shows an improvement in urinary symptoms and asymptomatic from the standpoint of bowel and sexual. At
12 months is detected PSA nadir (0.9ng/ml).
Conclusion. Intermediate risk patients are candidates mostly combined treatment (CRT+Brachytherapy), but there is a selected
subgroup, in which 100% of experts consulted agree deal with alone Brachytherapy: absence of perineural invasion, cT1c, <30%
cylinders (+) in the biopsy, Gleason 7 (3 + 4) or PSA 10–20ng/ml, obtaining a good control of the diseasewithout providing excessive
toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.022
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Introduction. The prostate cancer is the most frequent tumor in men; the radiotherapy and brachytherapy are an alternative
treatment highly effective and tolerable. In May of 2011 we have developed LDR brachytherapy technique in our unit, indicated
for low risk prostate cancer patients.
Objectives. To analyze the results in our experience by dosimetric parameters and acute toxicity and comparing with our previous
studies with HDR exclusive brachytherapy.
Material and methods. An observational retrospective study has been realized reviewing the dosimetric and clinics parameters of
44 low risk prostate cancer patients treated with LDR brachytherapy between May of 2011 and December of 2012.
Results. The mean age is 70 years (48–82). The dose administrated was 145Gy I-125. Dosimetric parameters: Prostate (V100: 96.4%,
D90: 114% y V150: 50%), urethra (D1%<160, D10%>150% y D30%>130%) and rectum (D2cc<145Gy y D1cc<160Gy). The treatment
tolerance was acceptable with those results on acute toxicity: dysuria 27.3%, pollakiuria 9%, strangury 25%, urgency 6.8%, acute
urinary retention 2.3%, urinary incontinence 6.8% and proctitis 4.5%. In HDR brachytherapy: The mean age is 71 years (50–79)
who received 34–36Gy in 4 fractions. Dysuria 18%, urgency 6.2%, acute urinary retention 15%, urinary incontinence 6.8% and
proctitis 5%, as acute toxicity.
Conclusions. The LDR brachytherapy is a good option for low risk prostate cancer treatment, based on the dosimetric parameters
and acute toxicity observed, like HDR, highlighting a decreased in acute urinary retention and urinary incontinence. We need
continue monitoring these patients and increased the number of patients included to reach more conclusions.
http://dx.doi.org/10.1016/j.rpor.2013.03.023
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Introduction. Patients with intermediate risk prostate neoplasms have been treated using ERBT plus radioactive implants Iodine
125 (LDR) to improve local control.
Material and methods. From 2004 to 2012, 99 ERBT plus LDR implants were performed. Patients (pts) had a median age of 64 (47–76);
Mean PSA is 7.4ng/ml (4–18); Gleason distribution was G6 9 pts (9.1%), G7 85 (85.9%) G8 4 pts (4%) G9 1 pts 1(1%). Tumor stage
distribution was T1 52 pts. (52.5%), T2 45 pts (45.5%), and T3 2 pts (2%). No patients with positive nodes or metastasis were
treated. External radiation therapy was administered on the prostate, seminal vesicles and a margin of safety, at a dose of 45Gy
in 3 cases, 46Gy in 88 cases, 48Gy in 1 case and 50Gy in 7 cases. After external radiotherapy brachytherapy was administered
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on prostate at a dose of 100Gy in 5 cases and 110Gy in 94 cases. Some type of hormone therapy was administered in 23 cases
(23.2%).
Results. The review was performed between 2011 and 2012. One patient did not have follow-up (treated in 2007). Overall, speciﬁc
and disease free survival at 5 years were 89% (CI 95% 84–92) 98% (CI 95% 96–100) and 93% (CI 95% 89–97) respectively. Biochemical
relapse at 5 years was 9% (CI 95% 5–15). No local relapses were found and only one patient with nodal relapse and one patient
with distant metastasis were observed. Acute toxicities were urinary in 17 pts (17%) 4 of them GIII (4%); rectal in 4 pts (4%).
Chronic toxicities were urinary in 15 pts (15%), 7 of them GIII (7%), 6 of them required catheter, 2 of them required suprapubic
cystostomy and 5 of them underwent transurethral resection.
Conclusions. Although efﬁcacy results are satisfactory, patients are adding up toxicities on both radiotherapy techniques.
http://dx.doi.org/10.1016/j.rpor.2013.03.024
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Purpose. Vaginal cuff brachytherapy (VBT) is one of the most widely and settle brachytherapy procedures wordwile. Some groups
advocate a previous rectum cleansing, despite this fact no studies exist analysing the consequences of rectal distention during
VBT. The aim of our study was to deﬁne how the type of rectal content affects its dosimetric values.
Material and methods. CT sets (337) derived from 92 patients treated with HDR-VBT were re-segmented and re-planed for study
purpose under the same parameters. Rectum content on each CT was recorded. Rectum DVH values were extracted and the dose
percentage related to the empty status was calculated. Parametric and non-parametric analysis was carried out according to the
rectal content.
Results. Dose percentages according to the rectal content and related to the empty status were: D0.1cc: feces 101.86, air 113.36,
air + feces 108, contrast 109.49, contrast + air 111.9; D1cc: feces 100.58, air 113.61, air + feces 107.62, contrast 111.75, contrast + air
112.96; D2cc: feces 100.4 air 114.53, air + feces 108.15, contrast 112.99, contrast + air 114.5; D5cc: feces 101.57, air 119.82, air + feces
111.95, contrast 117.6; contrast + air 120.27. Kruskal–Wallis (D5cc, D10cc) andANOVA (Dmax,D0.1cc, D2cc) tests showed signiﬁcant
differences among empty rectums, rectums with feces, and rectums with gas pockets (all p< .00001).
Conclusions. The presence of gas pockets increases rectal doses during vaginal cuff brachytherapy. Maneuvers addressed to reduce
it, like rectal tubes or rectum cleansing, could diminish rectal doses and toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.025
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Introduction. Endobronchial brachytherapy is an option in the treatment of airway tract tumors in centres where had experienced
staff. The indications are: localized endobronchial carcinomas, combined with external irradiation in ﬁrst line treatment of lung
cancers and palliative intention.
Objectives. To report our 5 years experience in brachytherapy for patients with respiratory tract cancer.
Methods. We carried out a retrospective review of our patients who underwent endobronchial brachytherapy from December
2007 to December 2012. Indications were radical, adjuvant and palliative intention. Under sedation, with local anesthesia and by
nasal access, the procedure involves the insertion of an afterloading 5F catheter into bronchus affected in close proximity to an
endoluminal lesion and to perform limited irradiation sparing as much as possible healthy tissues. CT dosimetry was performed
to verify catheter position anddose planning. In patientswith early stages (31.2%),we observed a patientwith complete remission
in a 3-years follow-up period.
Results. A total of 16 patients (14 men and 2 women) were reviewed: 11 with lung cancer, 4 esophagus and one tongue base. Types
of histology identiﬁed were: 12 squamous, 3 adenocarcinoma and only one with different histology. The mean patient’s age was
63.9 (46–79). The stages were: 6.2% 0, 25% I, 25% II, 31.25% III, 12.5% IV. Dose per fraction 500 cGy. One patient did not complete
treatment due to progression with occlusion of the bronchial lumen. One suffered from signiﬁcant toxicity: pneumothorax.
Other patients had minor toxicities: mucositis, dysphagia and cough. All patients who completed treatment showed good clinical
response (100%) and successful local control.
Conclusion. Endoluminal HDR brachytherapy in patients with respiratory tract cancer is a safe and effective treatment for improv-
ing local control and symptoms relief and also with radical intention in early stages.
http://dx.doi.org/10.1016/j.rpor.2013.03.026
